Johnson & Johnson at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2020 / 03:20PM GMT
Terence C. Flynn - Goldman Sachs Group Inc., Research Division - MD

Great. Good afternoon, everybody. Thanks for joining us. I'm Terence Flynn, the biopharma analyst at Goldman Sachs, and we're very pleased to be hosting Johnson & Johnson today at our virtual conference.

Joining us from the company is Jennifer Taubert, who is Executive Vice President and Chairman of Pharmaceuticals. Jennifer, thank you very much for your time today, and thank you for everything that the company is doing to combat COVID. I know you're going to start with some opening remarks before we go into the fireside chat.

Jennifer L. Taubert - Johnson & Johnson - Executive VP & Worldwide Chairman of Pharmaceuticals

Well, thanks, Terence, and good morning to everyone listening in. I'm so glad we found new ways to connect virtually during these unprecedented times, and I'm happy to spend some time with you today to talk about our Pharmaceuticals business.

I'd like to start by acknowledging all those who've been impacted by the recent events in the U.S. as well

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot